News from the FDA - Two new metastatic colorectal cancer treatments
https://www.facingourrisk.org/XRAY/news-from-FDA-colorectal-cancer-Mar-2024
Full article: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications
The FDA recently approved two new treatments for metastatic colorectal cancer. (Posted 3/22/24)
Questions To Ask Your Health Care Provider
- Am I eligible for any of the newly approved metastatic colorectal cancer treatments?
- What are the risk or benefits of LONSURF or Fruzaqla?
- Are there any clinical trials that I should consider?
Open Clinical Trials
The following studies are enrolling people with advanced colorectal cancer.
- NCT05217446: Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer with Certain Tumor Markers.This study is investigating the effects of using three study medicines together as treatment for previously untreated metastatic colorectal cancer.
- NCT03607890: Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor. This study evaluates the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors that were resistant to prior PD-(L)1 therapy.
- NCT05253651: Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting. This study evaluates whether the drug Tukysa (tucatinib) combined with other cancer drugs is more effective than the standard-of-care treatment in people with HER2-positive colorectal cancer.
- NCT02997228: Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study). The effort compares the effectiveness of combining chemotherapy and immunotherapy with an immunotherapy drug alone.
- NCT04008030: Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer.This study compares the combination of immunotherapy agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have MSI-H or dMMR metastatic colorectal cancer versus with nivolumab alone or chemotherapy alone.
- NCT04895722: Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer. This study compares the safety of a combination drug pembrolizumab/quavonlimab with four other treatments in patients with Microsatellite Instability-High (MSI-H) advanced colorectal cancer.
Several other clinical trials for patients with colorectal cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.